Checkpoint resubmits FDA application for cosibelimab (NASDAQ:CKPT)
2024-07-02
JHVEPhoto Checkpoint Therapeutics (NASDAQ:CKPT) said it has resubmitted its Biologics License Application to the FDA for its antibody treatment cosibelimab for the treatment of cutaneous squamous cell carcinoma, or cSCC. The biotech company said it filed the resubmission after reaching alignment with the FDA regarding deficiencies outlined in a CompleteContinue Reading